Advanced Embryology: How ICSI, MACS, and PGT-A Increase IVF Success Rates

When an IVF cycle does not lead to pregnancy, the question I often hear is: “Is there something more the laboratory can do?” It is an understandable question. Searching for “Advanced embryology IVF success” can bring up techniques that sound reassuringly sophisticated, but more technology does not automatically mean a better chance of taking home a baby.

In my practice, I explain advanced embryology as the careful use of laboratory expertise to support fertilisation, embryo development and selection. ICSI, MACS and PGT-A each address a different problem. My role is to help patients understand when these tools may be useful, where the evidence is uncertain, and how they fit into a personalised treatment plan.

What advanced embryology can change

IVF involves bringing eggs and sperm together in a laboratory, growing the resulting embryos and transferring an embryo into the uterus. Advanced embryology adds specific techniques to this process, but it cannot remove every biological limitation.

It helps to distinguish between fertilisation, implantation and live birth. Fertilisation means an egg has been successfully fertilised. Implantation means an embryo has attached to the uterine lining. A live birth is the outcome patients ultimately hope for. Improving one step does not necessarily improve all three.

When discussing IVF success, I therefore ask what an intervention is expected to improve. A higher pregnancy rate per embryo transfer, for example, does not necessarily mean a higher cumulative live birth rate from all embryos created during one egg collection.

Egg age, sperm quality, uterine health and laboratory standards all matter. For me, good care begins with identifying the likely difficulty rather than adding every available technique.

ICSI: supporting fertilisation when sperm need help

ICSI stands for intracytoplasmic sperm injection. An embryologist injects a single sperm directly into a mature egg, rather than allowing sperm to fertilise the egg in a laboratory dish.

I may recommend ICSI when there are very few sperm, poor sperm movement, significant sperm abnormalities or sperm obtained surgically. It can also be considered after unexpectedly poor or absent fertilisation in a previous conventional IVF cycle.

ICSI helps overcome certain barriers to fertilisation. However, it does not repair sperm DNA, reverse age-related changes in eggs or guarantee that a fertilised egg will become a healthy embryo.

Patients sometimes assume that ICSI is a superior version of IVF for everyone. I explain that, without a relevant indication, routine ICSI has not consistently shown a live birth advantage over conventional IVF. The choice should reflect the couple’s history and laboratory findings, not simply the availability of the technique.

There are also limitations: not every collected egg is mature enough for injection, some eggs may be damaged during the procedure, and fertilisation can still fail. These possibilities deserve a clear discussion beforehand.

MACS: understanding the promise and limits

MACS means magnetic-activated cell sorting. In fertility treatment, it is a sperm preparation technique intended to remove sperm showing certain markers associated with programmed cell death, a process called apoptosis.

The principle is to separate out potentially compromised sperm before the remaining sample is used for treatment, usually alongside other preparation methods. MACS does not repair sperm, and it cannot confirm that every sperm left behind has normal DNA.

This discussion sometimes arises after an abnormal sperm DNA fragmentation result. DFI, or DNA fragmentation index, describes the proportion of sperm with damaged DNA in a sample. It is different from a standard semen analysis, which assesses features such as sperm count and movement.

I do not recommend DFI testing or MACS automatically for every couple. Their relevance depends on the clinical history, and testing methods and interpretation can vary.

Although MACS has a plausible biological rationale, evidence that it reliably improves live birth rates remains limited and inconsistent. I discuss this uncertainty openly, particularly when patients are considering it after unsuccessful treatment.

I also look beyond the laboratory. Smoking, heat exposure, certain medical conditions and potentially treatable male reproductive problems may warrant attention. Assessment by a male fertility specialist can sometimes be more useful than immediately adding another laboratory procedure.

PGT-A and the wider treatment plan

PGT-A stands for preimplantation genetic testing for aneuploidy. “Aneuploidy” means an abnormal number of chromosomes, the structures that carry genetic information. The test assesses chromosome number in cells sampled from an embryo.

Usually, a few cells are taken from the outer layer of a blastocyst, an embryo that has developed for approximately five to seven days. These cells mainly contribute to the placenta. Embryos are generally frozen while results are processed.

PGT-A helps inform embryo selection; it does not make an embryo healthier. In selected circumstances, it may reduce transfers of embryos with chromosome abnormalities and reduce miscarriage per transfer. However, it has not consistently been shown to improve cumulative live birth rates for everyone undergoing IVF.

I may discuss it with patients of older reproductive age or in selected cases involving previous losses or unsuccessful treatment. None of these circumstances automatically makes testing the right choice. The number of available embryos, previous findings, costs and the patient’s priorities all matter.

Results are not always straightforward. A “mosaic” result suggests a mixture of chromosome findings in the sampled cells and requires specialist counselling. Sampling limitations, uncertain results and a small risk of embryo damage also need consideration. PGT-A does not test for every genetic condition or replace recommended prenatal screening or diagnostic discussions during pregnancy.

At Apollo Fertility, Kondapur, Hyderabad, I place these laboratory decisions within a broader assessment. This may include ovarian reserve testing and, where appropriate, a 3D ultrasound to assess uterine structure. AMH, or anti-Müllerian hormone, helps estimate likely ovarian response; it does not directly measure egg quality.

My preconception approach also includes balanced nutrition, appropriate activity, sleep and management of existing conditions. Yoga and mind-body care can support wellbeing without making patients responsible for treatment outcomes. Any naturopathy or supplement use needs safety review and must not replace evidence-based treatment.

Key takeaways

I see advanced embryology as a set of targeted tools, not a package everyone needs. ICSI can address specific fertilisation difficulties; MACS remains an option with uncertain live birth benefits; and PGT-A can guide embryo selection without guaranteeing a baby. The strongest plan combines a clear indication for each intervention, transparent discussion of limitations, careful laboratory practice and compassionate whole-person care. My aim is to optimise each patient’s chances while avoiding unnecessary procedures and keeping expectations realistic.

To schedule your personalized consultation with Dr. Munawwer Sana at Apollo Fertility in Kondapur, Hyderabad, or to arrange an online telehealth video consultation, click here to book your appointment.